

DAIS ANALYTIC CORP
Form 10-Q
August 14, 2009

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended June 30, 2009

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from _____ to _____

Commission File No. 333-152940

DAIS ANALYTIC CORPORATION
(Exact name of Registrant as specified in its charter)

New York

14-1760865

(State or other jurisdiction of incorporation or organization)

(IRS Employer Identification No.)

11552 Prosperous Drive, Odessa, FL 33556
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (727) 375-8484

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for at least the past 90 days. Yes No

Indicate by a check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "accelerated filer, large accelerated filer and smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Edgar Filing: DAIS ANALYTIC CORP - Form 10-Q

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

There were 19,080,037 shares of the Registrant's \$0.01 par value common stock outstanding as of August 13, 2009.

Dais Analytic Corporation

INDEX

	Page No.
Part I. Financial Information	
Item 1.	3
Financial Statements	
Balance Sheets June 30, 2009 (Unaudited) and December 31, 2008	3
Statements of Operations Three and six months ended June 30, 2009 and 2008 (Unaudited)	4
Statements of Stockholders' Deficit Six months ended June 30, 2009 (Unaudited)	5
Statements of Cash Flows Six months ended June 30, 2009 and 2008 (Unaudited)	6
Notes to Financial Statements (Unaudited)	7
Item 2.	16
Management's Discussion and Analysis of Financial Condition and Results of Operation	
Item 3.	22
Quantitative and Qualitative Disclosures About Market Risk	
Item 4T.	22
Controls and Procedures	
Part II. Other Information	22
Item 1.	22
Legal Proceedings	
Item 2.	23
Unregistered Sales of Equity Securities and Use of Proceeds	
Item 3.	23
Default Upon Senior Securities	
Item 4.	23
Submission of Matters to a Vote of Security Holders	
Item 5.	23
Other Information	
Item 6.	24
Exhibits	
Signatures	25

PART I—FINANCIAL INFORMATION

Dais Analytic Corporation
Balance Sheets

	June 30, 2009 (Unaudited)	December 31, 2008
Assets		
Current assets:		
Cash	\$ 34,888	\$ 26,867
Accounts receivable	273,564	188,970
Inventory	138,591	147,128
Loan costs, net of accumulated amortization	—	1,004
Prepaid expenses and other current assets	57,032	31,181
Total current assets	504,075	395,150
Property and equipment, net of accumulated depreciation of \$311,734 and \$307,286 at June 30, 2009 and December 31, 2008, respectively	22,486	26,933
Other assets:		
Deposits	2,280	2,280
Patents, net of accumulated amortization of \$101,327 and \$96,389 at June 30, 2009 and December 31, 2008, respectively	54,444	44,129
Total other assets	56,724	46,409
	\$ 583,285	\$ 468,492
Liabilities and Stockholders' Deficit		
Current liabilities:		
Accounts payable, including related party payables of \$130,321 and \$105,925 at June 30, 2009 and December 31, 2008, respectively	\$ 558,847	\$ 380,022
Accrued expenses, other	338,029	340,115
Accrued compensation and related benefits	1,245,189	1,147,389
Current portion of deferred revenue	84,145	84,145
Current portion of notes payable, net of unamortized discount of \$0 and \$30,137 at June 30, 2009 and December 31, 2008, respectively, including related party payable of \$62,524 and \$624 at June 30, 2009 and December 31, 2008, respectively	2,087,524	2,245,488
Total current liabilities	4,313,734	4,197,159
Long-term liabilities:		
Long-term portion of notes payable, net of unamortized discount of \$6,965	—	675,000
Deferred revenue, net of current portion	251,697	293,769
Total long-term liabilities	251,697	968,769
Stockholders' deficit:		
Series A preferred stock; \$.01 par value; 10,000,000 shares authorized; 0 shares issued and outstanding	187,740	121,624

Edgar Filing: DAIS ANALYTIC CORP - Form 10-Q

Common stock; \$.01 par value; 100,000,000 shares authorized; 18,773,969 and 12,162,398 shares issued; 18,516,756 and 11,905,185 shares outstanding at June 30, 2009 and December 31, 2008, respectively

Capital in excess of par value	26,872,179	25,253,196
Prepaid services paid for with common stock	—	(23,375)
Accumulated deficit	(29,769,953)	(28,776,769)
Treasury stock at cost, 257,213	(1,272,112)	(1,272,112)
Total stockholders' deficit	(3,982,146)	(4,697,436)
	\$ 583,285	\$ 468,492

The accompanying notes are an integral part of the financial statements.

Dais Analytic Corporation
Statements of Operations
(Unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2009	2008	2009	2008
Revenue:				
Sales	\$ 507,318	\$ 263,043	\$ 643,634	\$ 455,517
License fees	21,035	21,035	42,072	42,072
	528,353	284,078	685,706	497,589
Expenses:				
Cost of goods sold	337,574	218,057	444,544	377,990
Selling, general and administrative	439,426	502,304	982,798	1,758,403
	777,000	720,361	1,427,342	2,136,393
Loss from operations	(248,647)	(436,283)	(741,636)	(1,638,804)
Other expense (income):				
Interest expense	95,353	831,435	251,585	1,690,655
Interest income	—	(5,526)	(37)	(16,282)
	95,353	825,909	251,548	1,674,373
Net loss	\$ (344,000)	\$ (1,262,192)	\$ (993,184)	\$ (3,313,177)
Net loss per common share, basic and diluted	\$ (0.02)	\$ (0.13)	\$ (0.06)	\$ (0.36)
Weighted average number of common shares, basic and diluted	17,821,497	9,470,517	15,600,875	9,208,487

Dais Analytic Corporation
 Statements of Stockholders' Deficit
 For the Six Months Ended June 30, 2009

	Series A Preferred Stock		Common Stock			Accumulated Deficit	Prepaid Services Paid for with Common Stock		Treasury Stock	Stockholders' Deficit
	Shares	Amount	Shares	Amount	Capital in Excess of Par Value					
Balance, December 31, 2008	\$ -	\$ -	12,162,398	\$ 121,624	\$ 25,253,196	\$ (28,776,769)	\$ (23,375)	\$ (1,272,112)	\$ (4,697,436)	
Issuance of common stock for conversion of notes payable and related accrued interest (unaudited)	-	-	5,129,648	51,297	974,634	-	-	-	1,025,931	
Issuance of common stock and warrant for services (unaudited)	-	-	208,846	2,088	67,657	-	23,375	-	93,120	
Stock compensation expense (unaudited)	-	-	-	-	148,306	-	-	-	148,306	
Issuance of warrants for debt conversion (unaudited)	-	-	-	-	110,117	-	-	-	110,117	
Issuance of common stock and warrants for cash (unaudited)	-	-	1,273,077	12,731	318,269	-	-	-	331,000	
Net loss for the six months ended June 30, 2009 (unaudited)	-	-	-	-	-	(993,184)	-	-	(993,184)	

Balance, June
30, 2009

(unaudited) \$ - \$ - 18,773,969 \$ 187,740 \$ 26,872,179 \$ (29,769,953) - \$ (1,272,112) \$ (3,982,146)

The accompanying notes are an integral part of the financial statements.

Dais Analytic Corporation
Statements of Cash Flows
(Unaudited)

	Six Months Ended June 30,	
	2009	2008
Operating activities		
Net loss	\$ (993,184)	\$ (3,313,177)
Adjustments to reconcile net loss to net cash used by operating activities:		
Depreciation and amortization	9,385	8,464
Amortization of deferred loan costs	1,004	52,742
Amortization of discount on convertible notes	144	772,165
Amortization of the beneficial conversion feature on convertible notes	29,992	667,287
Write off of deferred noncash offering costs	—	55,000
Stock based compensation	148,306	946,202
Issuance of common stock for future services and amortization of common stock issued for future services	65,395	2,125
Issuance of common stock warrants for conversion of notes payable	110,117	43,111
Issuance of options and warrants for services	27,726	—
Value of beneficial conversion feature for conversion of notes payable and related accrued interest	—	21,708
(Increase) decrease in:		
Accounts receivable	(84,594)	(187,874)
Inventory	8,537	(44,933)
Prepaid expenses and other current assets	(25,851)	(5,832)
Increase (decrease) in:		
Accounts payable and accrued expenses	277,669	69,615
Accrued compensation and related benefits	97,800	21,876
Deferred revenue	(42,072)	(42,072)
Net cash used by operating activities	(369,626)	(933,593)
Investing activities		
Purchase of property and equipment	—	(14,647)
Increase in patents	(15,253)	—
Net cash used by investing activities	(15,253)	(14,647)
Financing activities		
Proceeds from issuance of notes payable	—	500,000
Proceeds of issuance of notes payable, related party	61,900	—
Proceeds received from escrow	—	1,000,000
Payments on notes payable	—	(100,000)
Payments for loan costs	—	(34,000)
Issuance of common stock for cash	331,000	—
Net cash provided by financing activities	392,900	1,366,000
Net increase in cash	8,021	417,760

Cash, beginning of period		26,867		504,232
Cash, end of period	\$	34,888	\$	921,992
Cash paid for interest	\$	403	\$	10,100

Supplemental disclosures of noncash investing and financing activities:

During the six months ended June 30, 2009, the Company issued 208,846 shares of common stock valued at \$69,745 for future services.

During the six months ended June 30, 2009, the Company issued 5,129,648 shares of common stock in conversion of \$925,000 of notes payable and \$100,930 of accrued interest.

During the six months ended June 30, 2008, the Company issued 240,000 shares of common stock valued at \$86,000 as payment for future services.

During the six months ended June 30, 2008, the Company issued 439,293 shares of common stock in conversion of \$100,000 of notes payable and \$8,540 of accrued interest.

During the six months ended June 30, 2008, the Company issued convertible notes payable with a beneficial conversion feature of \$245,106 and a discount equivalent to the relative fair value of the accompanying warrants of \$254,894.

The accompanying notes are an integral part of the financial statements.

Dais Analytic Corporation
Notes to Financial Statements
Three and Six Months Ended June 30, 2009
(Unaudited)

1. Background Information

Dais Analytic Corporation (the "Company"), a New York corporation, has developed and is commercializing applications using its nano-structure polymer technology. The first commercial product is an energy recovery ventilator ("ERV") (cores and systems) for use in commercial Heating, Ventilating, and Air Conditioning (HVAC) applications. In addition to direct sales, the Company licenses its nano-structured polymer technology to strategic partners in the aforementioned application and is in various stages of development with regard to other applications employing its base technologies. The Company was incorporated in April of 1993 with its corporate headquarters located in Odessa, Florida.

2. Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the six months ended June 30, 2009, the Company incurred a net loss of \$993,184. As of June 30, 2009, the Company has an accumulated deficit of \$29,769,953, negative working capital of \$3,809,659 and a stockholder's deficit of \$3,982,146 and is in default on notes in the aggregate principal amount of \$1,450,000. In view of these matters, there is substantial doubt that the Company will continue as a going concern. The recoverability of recorded property and equipment, intangible assets, and other asset amounts shown in the accompanying financial statements is dependent upon the Company's ability to continue as a going concern and to achieve a level of profitability. The Company intends on financing its future activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes and proceeds from sub-licensing agreements until such time that funds provided by operations are sufficient to fund working capital requirements. However, there can be no assurance that the Company will be successful in its efforts. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

3. Significant Accounting Policies

In the opinion of management, all adjustments consisting only of normal recurring adjustments necessary for a fair statement of (a) the results of operations for the three and six month periods ended June 30, 2009 and 2008, (b) the financial position at June 30, 2009 and December 31, 2008, and (c) cash flows for the six month periods ended June 30, 2009 and 2008, have been made.

The unaudited financial statements and notes are presented as permitted by Form 10-Q. Accordingly, certain information and note disclosures normally included in the financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted although the Company generally believes that the disclosures are adequate to ensure that the information presented is not misleading. The accompanying financial statements and notes should be read in conjunction with the audited financial statements and notes of the Company for the fiscal year ended December 31, 2008 included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2009 and the Company's quarterly report filed with the securities and Exchange Commission on May 20, 2009. The results of operations for the three and six month periods ended June 30, 2009 are not necessarily indicative of the results that may be expected for any future quarters or for the entire year ending December 31, 2009.

The significant accounting policies followed are:

Use of estimates - The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Dais Analytic Corporation
Notes to Financial Statements
Three and Six Months Ended June 30, 2009
(Unaudited)

3. Significant Accounting Policies (continued)

Loan and stock issuance costs - Direct loan costs incurred with the issuance of notes payable are deferred and amortized to interest expense over the life of the related notes payable. For the three months ended June 30, 2009 and 2008, the Company incurred amortization from direct loan costs of \$0 and \$28,888, respectively. For the six months ended June 30, 2009 and 2008, the Company incurred amortization from direct loan costs of \$1,004 and \$52,742, respectively.

Stock issuance costs are recorded as a reduction of the related proceeds through a charge to stockholders' equity.

Inventory - Inventory consists of raw materials and is stated at the lower of cost, determined by first-in, first-out method, or market. Market is determined based on the net realizable value, with appropriate consideration given to obsolescence, excessive levels, deterioration and other factors.

Revenue recognition - Generally, the Company recognizes revenue for its products upon shipment to customers, provided no significant obligations remain and collection is probable. Our ConsERV™ product typically carries a warranty of two years for all parts contained therein with the exception of the energy recovery ventilator core which typically carries a 10 year warranty. The warranty includes replacement of defective parts. A warranty reserve is recorded for estimated costs associated with potential warranty expenses on previous sales. Warranty cost has been immaterial to our overall operations. Revenue derived from the sale of licenses is deferred and recognized as revenue on a straight-line basis over the life of the license, or until the license arrangement is terminated. The Company recognized revenue of \$21,035 and \$42,072 from license agreements for each of the three and six month periods ended June 30, 2009 and 2008, respectively.

Employee stock options - In December 2004, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No. 123 (Revised 2004), "Share-Based Payment" (SFAS 123R). SFAS 123R requires all share-based payments to employees, including grants of employee stock options, to be recognized as compensation expense in the financial statements based on their fair values. That expense will be recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

The value of each grant under SFAS 123(R) is estimated at the grant date using the Black-Scholes option model with the following assumptions for options granted during the six month periods ended June 30, 2009 and 2008:

	Six Months Ended June 30, 2009	Six Months Ended June 30, 2008
Dividend rate	0%	0%
Risk free interest rate	1.65% – 3.21%	2.64% – 3.98%
Expected term	5 – 10 years	5 – 10 years
Expected volatility	92% – 105%	80% – 114%

The basis for the above assumptions are as follows: the dividend rate is based upon the Company's history of dividends; the risk-free interest rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant; the expected term was calculated based on the Company's historical pattern of options granted and the period of time they are expected to be outstanding; and expected volatility was calculated by review of a peer company's historical activity.

SFAS No. 123R requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Based on historical experience of forfeitures, the Company estimated forfeitures at zero percent for the six months ended June 30, 2009 and 2008 and incorporated this rate in the estimated fair value of employee option grants during 2009 and 2008.

Dais Analytic Corporation
Notes to Financial Statements
Three and Six Months Ended June 30, 2009
(Unaudited)

3. Significant Accounting Policies (continued)

Financial instruments – In September 2006, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No. 157 “Fair Value Measurements” (SFAS 157). SFAS 157 introduces a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. SFAS 157 for financial assets and liabilities is effective for fiscal years beginning after November 15, 2007. The Company adopted the standard for those financial assets and liabilities as of the 2008 fiscal year and the impact of adoption was not significant. SFAS 157 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. SFAS 157 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

- Level 1—Quoted prices in active markets for identical assets or liabilities.
- Level 2—Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable.
 - Level 3—Unobservable inputs that are supported by little or no market activity, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2009. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accounts receivable, prepaid and other current expenses, accounts payable, accrued compensation and accrued expenses. The fair value of the Company’s convertible notes payable is estimated based on current rates that would be available for debt of similar terms which is not significantly different from its stated value.

On January 1, 2009, the Company applied FAS No. 157, “Fair Value Measurements” (FAS 157), for all non-financial assets and liabilities measured at fair value on a non-recurring basis in accordance with FASB Staff Position (FSP) FAS 157-2, “Effective Date of FAS 157” (FSP 157-2), which postponed the effective date of FAS 157 for those assets and liabilities to fiscal years beginning after November 15, 2008, which for the Company is January 1, 2009. The application of FSP 157-2 did not have an impact on the Company’s financial position or results of operations.

Income taxes – Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due plus deferred taxes resulting from temporary differences. Such temporary differences result from differences in the carrying value of assets and liabilities for tax and financial reporting purposes. The deferred tax assets and liabilities represent the future tax consequences of those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

The Company has adopted the provisions of FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes”. The Company has not recognized a liability as a result of the implementation of Interpretation 48. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there is no unrecognized benefit since the date of adoption. The Company has not recognized interest expense or penalties as a result of the implementation of Interpretation 48.

Loss per share – Basic loss per share is computed by dividing net loss attributable to common stockholders by the weighted average common shares outstanding for the period. Diluted loss per share is computed giving effect to all potentially dilutive common shares. Potentially dilutive common shares may consist of incremental shares issuable upon the exercise of stock options and warrants and the conversion of notes payable to common stock. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered antidilutive and thus are excluded from the calculation. At June 30, 2009 and 2008, the Company had 42,535,122 and 41,247,638 potentially dilutive common shares, respectively, which were not included in the computation of loss per share because the effect would have been antidilutive. No shares potentially issuable to satisfy the in-the-money amount of our convertible notes payable have been included in the computation of diluted loss per share as the conversion options were not in-the-money.

Recent accounting pronouncements

In June 2009, the Financial Accounting Standards Board (FASB) issued SFAS No. 168, “The FASB Accounting Standards Codification and the Hierarchy of Generally Accepted Accounting Principles—a replacement of FASB Statement No. 162,” (SFAS 168). SFAS 168 replaces SFAS No. 162, “The Hierarchy of Generally Accepted Accounting Principles,” and establishes the FASB Accounting Standards Codification (Codification) as the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with GAAP. Rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws are also sources of authoritative GAAP for SEC registrants. The FASB will no longer issue new standards in the form of Statements, FASB Staff Positions, or Emerging Issues Task Force Abstracts; instead the FASB will issue Accounting Standards Updates. Accounting Standards Updates will not be authoritative in their own right as they will only serve to update the Codification. The issuance of SFAS 168 and the Codification does not change GAAP. SFAS 168 becomes effective for the Company for the period ending September 30, 2009. The adoption of SFAS 168 will not have an impact on the financial statements.

In June 2009, the FASB issued SFAS No. 167, “Amendments to FASB Interpretation No. 46(R),” (SFAS 167). SFAS 167 amends FASB Interpretation No. 46 (Revised December 2003), “Consolidation of Variable Interest Entities—an interpretation of ARB No. 51,” (FIN 46(R)) to require an enterprise to perform an analysis to determine whether the enterprise’s variable interest or interests give it a controlling financial interest in a variable interest entity; to require ongoing reassessments of whether an enterprise is the primary beneficiary of a variable interest entity; to eliminate the quantitative approach previously required for determining the primary beneficiary of a variable interest entity; to add an additional reconsideration event for determining whether an entity is a variable interest entity when any changes in facts and circumstances occur such that holders of the equity investment at risk, as a group, lose the power from voting rights or similar rights of those investments to direct the activities of the entity that most significantly impact the entity’s economic performance; and to require enhanced disclosures that will provide users of financial statements with more transparent information about an enterprise’s involvement in a variable interest entity. SFAS 167 becomes effective for the Company on January 1, 2010. Management is currently evaluating the potential impact of SFAS 167 on the financial statements.

Other recent accounting pronouncements issued by FASB (including EITF), the AICPA and the SEC did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Dais Analytic Corporation
Notes to Financial Statements
Three and Six Months Ended June 30, 2009
(Unaudited)

4. Notes Payable

Notes payable consist of the following at June 30, 2009:

Convertible notes payable; interest at 9%; maturing from December 2008 to October 2009, collateralized by the Company's patents and patent applications	\$ 2,025,000
Notes payable to a related party; non-interest bearing; due on demand; unsecured	62,524
Current portion of notes payable	\$ 2,087,524

Convertible Notes Payable.

During December 2007 and January 2008, the Company issued convertible promissory notes (the "Convertible Notes") and warrants to purchase common stock in exchange for proceeds totaling \$2,950,000. The Convertible Notes bear interest at 9% per annum and have stated maturity dates from December 2008 to January 2009. The Convertible Notes are repayable in cash or convertible into shares of the Company's stock at a rate of one share per \$0.20 of outstanding principle and interest. Warrants to purchase 14,750,000 shares of the Company's common stock accompanying the Convertible Notes are subject to certain limitations, exercisable at \$0.25 per share, vest immediately, and expire between December 2012 and January 2013.

The Convertible Notes contain an embedded conversion feature. The Company accounted for this conversion feature and detachable warrants in accordance with EITF Issue No. 98-5, "Accounting for Securities with Beneficial Conversion Feature or Contingently Adjustable Conversion Ratio," and EITF Issue No. 00-27, "Application of Issue No. 98-5 to Certain Convertible Instruments." In accordance with these standards, the Company allocated the proceeds from issuance of the convertible notes to the beneficial conversion feature and the warrants based on their relative fair values. The Company considered EITF No. 00-19 and concluded that the warrants should be recorded as a component of permanent equity.

To recognize the fair value of the warrants, the Company discounted the notes and increased additional paid in capital. The fair value of the beneficial conversion feature of \$1,383,437 and discount related to the warrants of \$1,566,563 were amortized over the term of the Convertible Notes. For the three months ended June 30, 2009 and 2008, the Company recognized interest expense from the amortization of the beneficial conversion feature and discount of \$0 and \$735,479, respectively. For the six months ended June 30, 2009 and 2008, the Company recognized interest expense from the amortization of the beneficial conversion feature and discount of \$30,136 and \$1,439,452, respectively.

The following table presents a reconciliation of the proceeds received from the financing to the carrying value of the Convertible Notes:

Principal balance of convertible notes	\$ 2,950,000
Relative fair value of the warrants	(1,566,563)
Beneficial conversion feature	(1,383,437)
Amortization of the discount	1,566,563
Amortization of the beneficial conversion feature	1,383,437

Conversion of notes payable into common stock	(925,000)
Carrying value at June 30, 2009	\$ 2,025,000

Between December 11, 2008 and January 21, 2009, all amounts due under the Convertible Notes matured and became due and payable in full. The Company has not repaid any of the amounts due under the respective Convertible Notes. The Company is currently proposing that holders of matured Convertible Notes either (i) convert their notes into shares at this time in exchange for additional warrants or (ii) extend the maturity of the Convertible Notes and continue to accrue interest. In December 2008 three investors extended the term of their Convertible Notes and in the six month period ending June 30, 2009 five investors extended the term of their Convertible Notes. The total face value of these Convertible Notes was \$575,000 of which \$475,000 in face value was extended to September of 2009 and the remainder to October of 2009. In addition, during the six months ended June 30, 2009 four investors converted the principal balance of \$925,000 plus accrued interest of \$100,930 on their Convertible Notes into 5,129,648 shares of common stock. These investors also received an additional 1,540,125 warrants, exercisable immediately at \$0.25 per share and valued at \$110,117, which was recorded as interest expense during the six months ended June 30, 2009.

Four investors holding Convertible Notes with an aggregate outstanding principal balance of approximately \$450,000 at December 31, 2008 had notified the Company that they were asserting their rights to receive payment of the principal and interest pursuant to the terms of the Convertible Notes. In June of 2009, three of these investors, holding an aggregate principal note balance of \$250,000, agreed to extend the term of their Convertible Notes to September 2009 in exchange for Company entering into a confession of judgment. Under that agreement, the three investors have the right, should the Company fail to pay all principal and interest due pursuant to their Convertible Notes on or before September 11, 2009, to file the confession of judgment with the court and seek to secure a judgment against the Company in the amount of all principal and interest due under their Convertible Notes together with the reasonable cost and expense of collection. The total number of investors extending their Convertible Notes and the face value of said Convertible Notes, as stated in the previous paragraph, is inclusive of these three investors and the aggregate face value of their Convertible Notes. In July of 2009, the fourth investor, who had previously provided notice and holds a Convertible Note in the principal amount of \$200,000, agreed to extend the Convertible Note to September 2009. . As of June 30, 2009, \$2,025,000 of convertible notes were outstanding, of which \$575,000 have been extended to September/October 2009 with the remaining notes due and payable in full.

Accrued interest on the notes was \$276,191 and \$268,453 at June 30, 2009 and December 31, 2008, respectively.

Dais Analytic Corporation
Notes to Financial Statements
Three and Six Months Ended June 30, 2009
(Unaudited)

5. Related Party Transactions

The Company rents a building that is owned by two stockholders of the Company, one of which is the Chief Executive Officer. Base rent expense is \$3,800 per month. The Company recognized rent expense of \$12,198 and \$24,396 in each of the three and six month periods ended June 30, 2009 and 2008, respectively. These amounts are not necessarily indicative of the amounts that would have been incurred had comparable transactions been entered into with independent parties. However, at the time the Company entered into the lease agreement, based on then current economic conditions, the real estate market, and the Company's prospects, the Company believed that the lease was on terms no less favorable to the Company than could generally be obtained from independent parties.

The Company also has accrued compensation due to the Chief Executive Officer and one other employee for deferred salaries earned and unpaid as of June 30, 2009 of \$1,245,189.

On May 21, 2009, to evidence a loan, Company issued its Chief Executive Officer a promissory note in the principal amount of \$51,900. The note is unsecured and bears a simple interest rate of 7% per annum. The principal amount plus all accrued interest is to be paid in full to the holder no later than July 31, 2009. This note was paid in full prior to July 31, 2009.

On June 10, 2009, to evidence a loan, the Company issued a promissory note in the principal amount of \$10,000 to Ethos Business Ventures, an entity in which its Chief Executive Officer holds a position. The note is unsecured and bears a simple interest rate of 7% per annum. The principal amount plus all interest accrued is to be paid in full to the holder no later than July 31, 2009. This note was paid in full prior to July 31, 2009.

6. Stock Options and Warrants

At June 30, 2009, the Company has a stock option plan (the "2000 Plan") that provides for the granting of options to qualified employees of the Company, independent contractors, consultants, directors and other individuals. As of June 30, 2009, the Company's Board of Directors approved and made available 11,093,882 shares of common stock to be issued pursuant to the 2000 plan. The 2000 Plan permits grants of options of common shares authorized and approved by the Company's Board of Directors for issuance prior to enactment of the 2000 Plan.

The following summarizes the information relating to outstanding stock options activity with employees during the 2009:

	Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term in years)	Aggregate Intrinsic Value
Shares under option at December 31, 2008	8,606,556	\$ 0.27		
Granted	-	-		

Edgar Filing: DAIS ANALYTIC CORP - Form 10-Q

Exercised	-	-		
Forfeited or expired	(172,732)	\$	0.32	
Outstanding at June 30, 2009	8,433,824	\$	0.25	7.07 \$ 95,984
Exercisable at June 30, 2009	8,081,768	\$	0.25	6.73 \$ 95,984

Dais Analytic Corporation
Notes to Financial Statements
Three and Six Months Ended June 30, 2009
(Unaudited)

Stock compensation expense was \$69,591 and \$148,306 for the three and six month periods ending June 30, 2009, respectively. Stock compensation expense was \$74,448 and \$946,202 for the three and six months ended June 30, 2008, respectively.

6. Stock Options and Warrants (continued)

As of June 30, 2009, there was \$307,093 of unrecognized employee stock-based compensation expense related to non vested stock options. This expense will be recognized over a weighted average period of .92 years.

The following table represents our non vested share-based payment activity for the six months ended June 30, 2009:

	Number of Options	Weighted Average Grant Date Fair Value
Nonvested options - December 31, 2008	1,276,563	\$ 0.37
Granted	-	
Vested	(894,175)	
Forfeited	(30,333)	
Nonvested options – June 30, 2009	352,055	\$ 0.22

Warrants and Options

At June 30, 2009, the Company had outstanding warrants and options to purchase the Company's common stock which were issued in connection with multiple financing arrangements, consulting agreements and employment agreements. Information relating to these warrants and options is summarized as follows:

	Remaining Number Outstanding	Weighted Average Remaining Life (Years)	Weighted Average Exercise Price
Warrants			
Warrants-Daily Financing	197,055	2.49	\$ 0.55
Warrants-Additional Financing	428,637	3.21	\$ 0.40
Warrants-Robb Trust Note	50,000	2.93	\$ 0.55
Warrants-Financing	14,750,000	1.83	\$ 0.25
Warrants-Placement Agent Warrants	1,792,308	3.67	\$ 0.25
Warrants-Tangredi	3,000,000	3.76	\$ 0.36
Warrants-Ehrenberg	250,000	4.10	\$ 0.30
Warrants-Consulting Agreement	250,000	4.84	\$ 0.26
Warrants-Note Conversions	1,540,125	4.73	\$ 0.25
Warrants-Stock Purchases 2009	636,439	4.84	\$ 0.26
Options-Mandelbaum	200,000	4.84	\$ 0.19

Total	23,094,564
-------	------------

7. Commitments and Contingencies

The Company has employment agreements with some of its key employees and executives. These agreements provide for minimum levels of compensation during current and future years. In addition, these agreements call for grants of stock options and for payments upon termination of the agreements.

Between December 11, 2008 and January 21, 2009, all amounts due under the Convertible Notes matured and became due and payable in full. The Company has not repaid any of the amounts due under the respective Convertible Notes. In 2009 four investors with outstanding principal balances of approximately \$450,000 in the aggregate, notified the Company that they were asserting their rights to receive payment of the principal and interest pursuant to the terms of the Convertible Notes. In June of 2009, three of these investors, holding an aggregate principal note balance of \$250,000, agreed to extend the term of their Convertible Notes to September 2009 in exchange for Company entering into a confession of judgment. Under that agreement, the three investors have the right, should the Company fail to pay all principal and interest due pursuant to their Convertible Notes on or before September 11, 2009, to file the confession of judgment with the court and seek to secure a judgment against the Company in the amount of all principal and interest due under their Convertible Notes together with the reasonable cost and expense of collection. In July of 2009, the fourth investor, who had given notice and holds a Convertible Note in the principal amount of \$200,000, agreed to extend the Convertible Note to September 2009. The Company is currently proposing that the holder of matured Convertible Notes either (i) convert their notes into shares at this time in exchange for additional warrants or (ii) extend the maturity of the Convertible Notes and continue to accrue interest. Certain investors have extended the maturity dates of their notes or converted their notes to common stock.

The Company entered into an agreement with the holders of the Convertible Notes to file a registration statement within a defined timeframe. The Company will incur penalties and damages of up to approximately \$236,000 if it does not file and keep the registration statement effective pursuant to the terms of this agreement. As of June 30, 2009, the Company has recorded a liability of \$41,000 related to this agreement.

In June 2008, the Company hired a consultant to assist in evaluating possible environmental credit opportunities. A portion of any such credits obtained, or revenue generated from the sale thereof, is payable by the Company to the consultant.

8. Subsequent Events

During July 2009, the Company issued a \$300,000 note payable to an investor. The note bears 7% interest per annum, however, the repayment terms have yet to be finalized.

During July 2009, an investor holding a Convertible Note in the principal amount of \$200,000 agreed to extend the term of his Convertible Note to September 2009.

In August of 2009, an investor elected to convert his Convertible Note and the related accrued interest in the amount of \$85,541 into 427,706 shares of the Company's common stock. The investor also received an additional warrant to purchase up to 124,875 shares of Company's common stock, at an exercise price of \$.25 per share in consideration for converting the Convertible Note.

In August 2009 the Company entered an agreement describing the terms and conditions under which a Consultant serves as the Chief Financial Officer. As payment for said services, Company has issued the Consultant an option to purchase 200,000 shares of the Company's common stock and will make a cash payment to Consultant of \$3,333 per month. The 200,000 options shall be exercisable at a price of \$.19 per share for a period of 10 years from the option grant date and will vest as follows: (i) 50,000 options upon the three month anniversary of the option grant date, and (ii) 50,000 options shall vest every three (3) months thereafter until the entire number of options is vested.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the notes thereto included elsewhere in this quarterly report on Form 10-Q and in our Form 10K filed with the Securities and Exchange Commission on March 31, 2009.

THIS FILING, INCLUDING BUT NOT LIMITED TO "MANAGEMENT'S DISCUSSION AND ANALYSIS", CONTAINS FORWARD-LOOKING STATEMENTS. THE WORDS "ANTICIPATED," "BELIEVE," "EXPECT," "PLAN," "INTEND," "SEEK," "ESTIMATE," "PROJECT," "WILL," "COULD," "MAY," AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. THESE STATEMENTS INCLUDE, AMONG OTHERS, INFORMATION REGARDING FUTURE OPERATIONS, FUTURE CAPITAL EXPENDITURES, AND FUTURE NET CASH FLOW. SUCH STATEMENTS REFLECT THE COMPANY'S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND FINANCIAL PERFORMANCE AND INVOLVE RISKS AND UNCERTAINTIES, INCLUDING, WITHOUT LIMITATION, GENERAL ECONOMIC AND BUSINESS CONDITIONS, CHANGES IN FOREIGN, POLITICAL, SOCIAL, AND ECONOMIC CONDITIONS, REGULATORY INITIATIVES AND COMPLIANCE WITH GOVERNMENTAL REGULATIONS, THE ABILITY TO ACHIEVE FURTHER MARKET PENETRATION AND ADDITIONAL CUSTOMERS, AND VARIOUS OTHER MATTERS, MANY OF WHICH ARE BEYOND THE COMPANY'S CONTROL. OUR ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE ANTICIPATED IN THESE FORWARD-LOOKING STATEMENTS AS A RESULT OF SEVERAL FACTORS, INCLUDING THE RISKS FACED BY US AS DESCRIBED BELOW AND ELSEWHERE IN THIS FORM 10-Q AS WELL AS IN OUR FORM 10-K FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MARCH 31, 2009. IN LIGHT OF THESE RISKS AND UNCERTAINTIES THERE CAN BE NO ASSURANCE THAT THE FORWARD-LOOKING STATEMENTS CONTAINED IN THIS FORM 10-Q WILL OCCUR. WE HAVE NO OBLIGATION TO PUBLICLY UPDATE OR REVISE THESE FORWARD-LOOKING STATEMENTS TO REFLECT NEW INFORMATION, FUTURE EVENTS, OR OTHERWISE, EXCEPT AS REQUIRED BY FEDERAL SECURITIES LAWS AND WE CAUTION YOU NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS. WE MAY NOT UPDATE THESE FORWARD-LOOKING STATEMENTS, EVEN THOUGH OUR SITUATION MAY CHANGE IN THE FUTURE.

OVERVIEW

We have developed and patented a nano-structure polymer technology, which is being commercialized in products based on the functionality of these materials. We believe the applications of our technology have promise in a number of diverse market segments and products.

The initial product focus of the Company is ConsERV, an energy recovery ventilator. Our primary focus is to expand our marketing and sales of our ConsERV™ product.

We also have new product applications in various developmental stages. We believe that three of these product applications, including an advanced air conditioning system which is projected to use less energy and emits fewer emissions than current HVAC equipment, a sea-water desalination product and an electrical energy storage device, can be brought to market in the foreseeable future if we receive adequate capital funding.

REVENUES

We generate our revenues primarily from the sale of our ConsERV™ products in residential and commercial HVAC markets. Sales channels for our ConsERV™ products include OEMs, distributors, retailers, and consumers. We also

occasionally license our technology to strategic partners and sell various prototypes of other product applications that use our polymer technology.

Our revenue growth is dependent on continued sales from (i) more seasoned independent sales representatives, (ii) a greater number of independent sales representatives (iii) fulfilling the ventilation needs of the growing “energy consultant” marketplace which work to lower their client’s energy costs and emissions, and (iv) from the Company’s own ‘customer direct’ sales activities, all of which focus on the sale of product primarily into the commercial user marketplace with a growing emphasis on low rise structures (small commercial buildings, multi-purpose structures, and residences). In addition, the Company and its independent sales representative sales force will work to secure orders for ConServ “core only” sales (i) from HVAC equipment manufacturers, (ii) from distribution firms servicing the equipment needs of the HVAC installer community, and (iii) creating license/supply relationships to HVAC or ERV OEMs preferably having a dominant presence in existing direct related sales channels.

COST OF SALES

Our cost of sales consists primarily of materials (including freight), direct labor, and outsourced manufacturing expenses incurred to produce our ConsERV™ products.

We are dependent on third parties to manufacture the key components needed for our nano-structured based materials and value added products made with these materials. Accordingly, a supplier's failure to supply components in a timely manner, or to supply components that meet our quality, quantity and cost requirements or our technical specifications, or the inability to obtain alternative sources of these components on a timely basis or on terms acceptable to us, would create delays in production of our products or increase our unit costs of production. Certain of the components contain proprietary products of our suppliers, or the processes used by our suppliers to manufacture these components are proprietary. If we are required to replace any of our suppliers, while we should be able to obtain comparable components from alternative suppliers at comparable costs, this would create a delay in production.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

Our selling, general and administrative expenses consist primarily of payroll and related benefits, share-based compensation, professional fees, marketing and channel support costs, and other infrastructure costs such as insurance, information technology and occupancy expenses.

Results of Operations

The following table sets forth, for the periods indicated, certain data derived from our Statements of Operations and certain of such data expressed as a percentage of revenues:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2009	2008	2009	2008
Revenues	\$ 528,353	\$ 284,078	\$ 685,706	\$ 497,589
Percentage of revenues	100%	100.0%	100%	100.0%
Cost of goods sold	\$ 337,574	\$ 218,057	\$ 444,544	\$ 377,990
Percentage of revenues	63.9%	76.8%	64.8%	76.0%
Selling, general and administrative expenses	\$ 439,426	\$ 502,304	\$ 982,798	\$ 1,758,403
Percentage of revenues	83.2%	176.8%	143.3%	353.4%
Interest expense	\$ 95,353	\$ 831,435	\$ 251,585	\$ 1,690,655
Percentage of revenues	18.0%	292.7%	36.7%	339.8%
Net loss	\$ (344,000)	\$ (1,262,192)	\$ (993,184)	\$ (3,313,177)
Percentage of revenues	(65.1)%	(444.3)%	(144.8)%	(665.9)%

Summary of Three Months Ended June 30, 2009 Results of Operations

REVENUES: Total revenues for the three months ended June 30, 2009 and 2008 were \$528,353 and \$284,078, respectively, an increase of \$244,275 or 86%. The increase in revenues in the 2009 period is primarily attributable to the Company increasing the sales price of the ConsERV products and an increase in the number and magnitude of its sales transactions. The Company also attributes the sales increase to a realignment of its independent sales representatives, the increase in the number of such sales representatives and the hiring of an additional internal sales person and engineer to support its sales staff. During the three months ended June 30, 2009 and 2008, four and two customers accounted for approximately 69% and 73% of revenues, respectively.

COST OF GOODS SOLD: Cost of goods sold increased \$119,517 to \$337,574 and represented 63.9% of revenues, for the three months ended June 30, 2009 compared to \$218,057 or 76.8% of revenues for the three months ended June 30, 2008. The increase in cost of goods sold during 2009 is primarily due to the increase in sales. The decrease in cost of goods sold as a percentage of revenue in 2009 is primarily attributable to a decrease in the cost of materials due to the implementation of improvements to the production process of certain product components and outsourcing some of the production in order to maximize the gross margin.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES: Selling, general and administrative expenses of \$439,426 for the three months ended June 30, 2009 decreased \$62,878 from \$502,304 in the same period of 2008 or 12.5%. This decrease is primarily due to a decrease of \$66,900 in payroll expenses due, in part, to a salary adjustment initiated in April of 2009 and a decrease of 11,900 in air travel as the prior year contained additional travel to establish new customers and investigating potential vendors. These decreases were partially offset by an increase in insurance costs of \$19,600 which is mainly due to an increase in the Company's Director's and Officer's insurance policy as the Company is now a publicly reporting entity.

INTEREST EXPENSE: Interest expense was \$95,353 for the three months ended June 30, 2009 compared to \$831,435 for the same period of 2008, a decrease of \$736,082. During the three months ended June 30, 2009, interest expense was related to convertible notes issued from December 2007 to January 2008 of approximately \$46,900 and approximately \$46,900 in expense relating to warrants issued to induce conversion of principal and interest accrued on two convertible notes having a principal value of \$250,000. Interest expense for the three months ended June 30, 2008 relates primarily to amortization of the beneficial conversion feature and discount on outstanding notes payable. The decrease in interest expense in 2009 is due to fact that the beneficial conversion feature and discount on the notes payable was fully amortized at April 1, 2009.

NET LOSS: Net loss for the three months ended June 30, 2009 decreased by \$918,192 to \$344,000 from \$1,262,192 for the three months ended June 30, 2008. The decrease in net loss is primarily due to the increase in gross margin, coupled with the decreases in selling, general and administrative expenses and interest expense as discussed above.

Summary of Six Months Ended June 30, 2009 Results of Operations

REVENUES: Total revenues for the six months ended June 30, 2009 and 2008 were \$685,706 and \$497,589, respectively, an increase of \$188,117 or 37.8%. The increase in revenues in 2009 is primarily attributable to the Company increasing the sales price of the ConsERV products and increasing the number and magnitude of its sales transactions. The Company also attributes the increase in sales to its realignment of its independent sales representatives, the increase in the number of such sales representatives and hiring of an additional internal sales person and engineer to support its sales staff. During the six months ended June 30, 2009 and 2008, four and two customers accounted for approximately 68% and 73% of revenues, respectively.

COST OF GOODS SOLD: Cost of goods sold increased \$66,554 to \$444,544 and represented 64.8% of revenues, for the six months ended June 30, 2009 compared to \$377,990 or 76.0% of revenues for the six months ended June 30, 2008. The increase in cost of goods sold in 2009 is primarily a factor of the increase in sales. The decrease in cost of goods sold as a percentage of revenue in 2009 is primarily attributable to a decrease in the cost of materials due to the implementation of improvements to the production process of certain product components and outsourcing some of the production in order to maximize the gross margin.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES: Selling, general and administrative expenses of \$982,798 for the six months ended June 30, 2009 decreased \$775,605 from \$1,758,403 in the same period of 2008 or 44.1%. This decrease is primarily due to a decrease in stock based compensation awards of approximately \$798,200 as there were no awards given during 2009 and the Company granted a large stock compensation award during 2008. Also, there was a decrease in payroll expenses of approximately \$20,100, due to a companywide temporary reduction in salaries. These decreases were partially offset by an increase in insurance costs of approximately \$17,900 due to the higher cost of Director's and Officer's Liability Insurance and during the later part of 2008 and an increase of approximately \$25,600 in legal and accounting fees due to increased year-end audit costs.

INTEREST EXPENSE: Interest expense was \$251,585 for the six months ended June 30, 2009 compared to \$1,690,655 for the same period of 2008, a decrease of \$1,439,070. During the six months ended June 30, 2009, interest expense was related to convertible notes issued from December 2007 to January 2008, including approximately \$108,900 of interest payable to the convertible note holders and approximately \$110,100 in expense relating to warrants issued to induce conversion of principal and interest accrued on four convertible notes having a principal value of \$925,000. Interest expense for the six months ended June 30, 2008 relates primarily to amortization of the beneficial conversion feature discount on outstanding notes payable. The decrease in interest expense is due to fact that the beneficial conversion feature and discount on the notes payable became fully amortized in January 2009.

NET LOSS: Net loss for the six months ended June 30, 2009 decreased by \$2,319,993 to \$993,184 from \$3,313,177 for the six months ended June 30, 2008. The decrease in the net loss is primarily due to the increase in gross margin in 2009, coupled with the decreases in selling, general and administrative expenses and interest expense as discussed above.

Liquidity and Capital Resources

The Company finances its operations primarily through sales of its ConsERV™ products, sales of its common stock, the issuance of convertible promissory notes and license agreements.

Our historical revenues have not been sufficient to sustain our operations. We have not achieved profitability in any year since inception and we expect to continue to incur net losses and negative cash flow from operations until we can produce sufficient revenues to cover our costs, which is not expected for several years. Furthermore, even if we achieve our projection of selling a greater number of ConsERV™ units, we anticipate that we will continue to incur losses until we can cost-effectively produce and sell our products to a wider market. Our profitability will require the successful commercialization of our ConsERV™ products and any future products we develop. No assurances can be given when this will occur.

In December 2007 and January 2008 we issued \$2,950,000 of one year Convertible Notes. At June 30, 2009, we had outstanding debt from these 9% convertible secured promissory notes of \$ 2,025,000 plus related interest. The notes matured commencing in December 2008 through January 2009. We did not have adequate funds to repay the notes upon maturity. The notes are secured by all of the Company's patents and the majority of the Company's patent applications. The Company is currently proposing that holders of matured Convertible Notes either (i) convert their notes into shares at this time in exchange for additional warrants or (ii) extend the maturity of the Convertible Notes and continue to accrue interest. In December 2008 three investors extended the term of their Convertible Notes and in the six month period ending June 30, 2009, five investors extended the term of their Convertible Notes. The total face value of these Convertible Notes was \$575,000 of which \$475,000 in face value was extended to September of 2009 and the remainder to October of 2009. In addition, during the six months ended June 30, 2009 four investors converted the principal balance of \$925,000 plus accrued interest of \$100,930 on their Convertible Notes into 5,129,648 shares of common stock. For agreeing to convert their Convertible Notes, these investors also received an additional 1,540,125 warrants, exercisable immediately at \$0.25 per share and valued at \$110,117, which was recorded as interest expense during the six months ended June 30, 2009.

Four investors holding Convertible Notes with an aggregate outstanding principal balance of approximately \$450,000 at December 31, 2008 had notified the Company that they were asserting their rights to receive payment of the principal and interest pursuant to the terms of the Convertible Notes. In June of 2009, three of these investors, holding an aggregate principal note balance of \$250,000, agreed to extend the term of their Convertible Notes to September 2009. The Company delivered to these investors a confession of judgment to be filed with the court if the Company fails to pay all principal and interest due pursuant to their Convertible Notes on or before September 11, 2009. If the confession of judgment is filed, these investors may seek to secure a judgment against the Company in the amount of all principal and interest due under their Convertible Notes together with the reasonable cost and expense of collection. The total number of investors extending their Convertible Notes and the face value of said Convertible Notes, as stated in the previous paragraph, is inclusive of these three investors and the aggregate face value of their Convertible Notes. In July of 2009, the fourth investor, who had previously provided notice and holds a Convertible Note in the principal amount of \$200,000, agreed to extend the Convertible Note to September 2009. As of June 30, 2009, \$2,025,000 of convertible notes were outstanding, of which \$575,000 have been extended to September/October 2009 with the remaining notes due and payable in full.

The Company may not be able to secure additional financing to repay the notes on acceptable terms, if at all, and we are currently unable to pay the notes that have matured. As an alternative, management may attempt to renegotiate the repayment terms of the notes and seek extension of the maturity dates. There is no guarantee that any re-negotiated terms we may be able to secure would be favorable to the Company. Unfavorable terms, in either a financing transaction or debt renegotiation, would adversely impact our business, financial condition and/or results of operations. In the event (i) we are unable to secure additional financing sufficient to pay the notes, (ii) the notes are

not converted into shares of our common stock pursuant to their terms, or (iii) we are not able to negotiate extensions to the maturity dates of the notes, note holders will have the option to foreclose on all of our patents and those patent applications securing the notes, which would likely result in the failure of our business.

Any future financing may result in substantial dilution to existing shareholders, and future debt financing, if available, may include restrictive covenants or may require us to grant a lender a security interest in any of our assets not already subject to an existing security interest. To the extent that we attempt to raise additional funds through third party collaborations and/or licensing arrangements, we may be required to relinquish some rights to our technologies or products currently in various stages of development, or grant licenses or other rights on terms that are not favorable to us. Any failure by us to timely procure additional financing or investment adequate to fund our ongoing operations, including planned product development initiatives, clinical studies and commercialization efforts, will have material adverse consequences on our financial condition, results of operations and cash flows.

We will be dependent upon our existing cash of \$34,888 at June 30, 2009, product sales, a recent loan of \$300,000 (received in July 2009) from one of our investors and additional debt and equity issuances to finance our operations through the next 12 months. We need to raise additional capital of approximately \$13 to \$18 million, net of offering costs, during the next nine to twelve months, the proceeds of which will be used to pay down existing debt, secure new patents for innovative applications of our core technology, purchase equipment, and fund our working capital requirements through June 30, 2010. We currently have no commitments for any such funds.

Our ability to continue as a going concern is highly dependent on our ability to obtain additional sources of cash flow sufficient to fund our working capital requirements, including repayment of our debt obligations. We intend to finance our operations, including the repayment of notes payable, primarily through private sales of debt and equity securities, licensing revenues, and sales of non-core uses of our technology. Any failure by us to timely secure the cash flow adequate to fund our debt obligations and ongoing operations will have a materially adverse consequence on our financial condition, results of operations and cash flows.

Statement of Cash Flows

The following table sets forth, for the periods indicated, selected cash flow information:

	Six Months Ended June 30,	
	2009	2008
Cash flows used in operating activities	\$ (369,626)	\$ (933,593)
Cash flows used in investing activities	(15,253)	(14,647)
Cash flows provided by financing activities	392,900	1,366,000
Net increase in cash and cash equivalents	\$ 8,021	\$ 417,760

During the six months ended June 30, 2009, cash used in operating activities consisted of our net loss of \$993,184, less non-cash adjustments such as issuance of stock options and warrants for services and debt conversions totaling \$373,807 and also adjusted for cash provided by increases in accounts payable and accrued expenses of \$277,669, as well as other changes in operating assets and liabilities. Financing activities provided \$392,900 of cash from net proceeds from the issuance of common stock of \$331,000 and \$61,900 proceeds from the issuance of a note payable.

During the six months ended June 30, 2008, the cash flows provided by financing activities was mainly attributable to the issuance of convertible notes payable and the release of escrow cash related to the convertible notes payable.

ECONOMY AND INFLATION

Except as disclosed herein, we have not experienced any significant cancellation of orders due to the downturn in the economy and only a small number of customers requested delays in delivery or production of orders in process. Our management believes that inflation has not had a material effect on our results of operations.

OFF-BALANCE SHEET ARRANGEMENTS

We do not have any off balance sheet arrangements that are reasonably likely to have a current or future effect on our financial condition, revenues, and results of operations, liquidity or capital expenditures.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4T. CONTROLS AND PROCEDURES

Evaluation of disclosure controls and procedures

Our Chief Executive Officer and Chief Financial Officer (collectively the “Certifying Officers”) maintain a system of disclosure controls and procedures that is designed to provide reasonable assurance that information, which is required to be disclosed, is accumulated and communicated to management timely. The Certifying Officers have concluded that the disclosure controls and procedures are effective at the “reasonable assurance” level. Under the supervision and with the participation of management, as of the end of the period covered by this report, the Certifying Officers evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act). Furthermore, the Certifying Officers concluded that our disclosure controls and procedures in place are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported on a timely basis in accordance with applicable Commission rules and regulations; and (ii) accumulated and communicated to our management, including our Certifying Officers and other persons that perform similar functions, if any, to allow us to make timely decisions regarding required disclosure in our periodic filings.

Changes in Internal Control Over Financial Reporting

No change in the Company’s internal control over financial reporting occurred during the six months ended June 30, 2009, that materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

Part II — OTHER INFORMATION

Item 1. Legal Proceedings

The status of our legal proceedings, as disclosed in our Annual Report remains unchanged.

The Company is party to lawsuits from time to time arising in the ordinary course of its businesses. The Company provides for costs relating to these matters when a loss is probable and the amount is reasonably estimable. The effect of the outcome of these matters on the Company's future results of operations cannot be predicted because any such effect depends on future results of operations and the amount and timing of the resolution of such matters.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Other than as disclosed in our Form 8-K, filed with the Securities and Exchange Commission on July 7, 2009 and 48,000 shares of common stock issued to a consultant pursuant to an extension of a consulting agreement, Company has not issued securities during the period pertaining to this Form 10-Q filing.

Item 3. Defaults Upon Senior Securities

Other than disclosed in Company's Form 8-K filings with the Securities and Exchange Commission there have been no defaults in any material payments during the covered period.

Item 4. Submission of Matters to a Vote of Security Holders

During the three months ended June 30, 2009, the Company did not submit any matters to a vote of its security holders.

Item 5. Other Information

In August 2009 the Company entered an agreement describing the terms and conditions under which a Consultant serves as the Chief Financial Officer. As payment for said services, Company has issued the Consultant an option to purchase 200,000 shares of the Company's common stock and will make a cash payment to Consultant of \$3,333 per month. The 200,000 options shall be exercisable at a price of \$.19 per share for a period of 10 years from the option grant date and will vest as follows: (i) 50,000 options upon the three month anniversary of the option grant date, and (ii) 50,000 options shall vest every three (3) months thereafter until the entire number of options is vested.

Item 6. Exhibits

No.	Item 6 – Exhibits
3.1	Certificate of Incorporation of The Dais Corporation filed April 8, 1993*
3.2	Certificate of Amendment of the Certificate of Incorporation of The Dais Corporation filed February 21, 1997*
3.3	Certificate of Amendment of the Certificate of Incorporation of The Dais Corporation filed June 25, 1998*
3.4	Certificate of Amendment of the Certificate of Incorporation of Dais Analytic Corporation filed December 13, 1999*
3.5	Certificate of Amendment of the Certificate of Incorporation of Dais Analytic Corporation filed September 26, 2000*
3.6	Certificate of Amendment of the Certificate of Incorporation of Dais Analytic Corporation filed September 28, 2000*
3.7	Certificate of Amendment of the Certificate of Incorporation of Dais Analytic Corporation filed August 28, 2007*
3.8	Certificate of Amendment of the Certificate of Incorporation of Dais Analytic Corporation filed March 20, 2008*
3.9	Bylaws of The Dais Corporation*
4.1	Form of Non-Qualified Stock Option Agreement*
4.2	Form of Non-Qualified Option Agreement*
4.3	Form of Warrant (Daily Financing)*
4.4	Form of Warrant (Financing)*
4.5	Form of Warrant (Robb Trust Note and Additional Financing)*
4.6	Form of Placement Agent Warrant (Financing)*
4.7	Form of 9% Secured Convertible Note (Financing)*
4.8	Form of Note (Robb Trust Note)*
4.9	Form of Amendment to Note (Robb Trust Note)*
4.10	Form of Warrant (Note Conversion)**
4.11	Form of Warrant (Gostomski and Weston)**
10.1	2000 Equity Compensation Plan*
10.2	Form of Employee Non-Disclosure and Non-Compete Agreement*
10.3	Amended and Restated Employment Agreement between Dais Analytic Corporation and Timothy N. Tangredi dated July 29, 2008*
10.4	Amended and Restated Employment Agreement between Dais Analytic Corporation and Patricia K. Tangredi dated July 29, 2008*
10.5	Commercial Lease Agreement between Ethos Business Venture LLC and Dais Analytic Corporation dated March 18, 2005*
10.6	First Amendment of Lease Agreement between Ethos Business Venture LLC and Dais Analytic Corporation dated November 15, 2005*
10.7	Form of Subscription Agreement (Daily Financing)*
10.8	Form of Subscription Agreement (Financing)*
10.9	Form of Registration Rights Agreement (Financing)*
10.10	Form of Secured Patent Agreement (Financing)*
10.11	Placement Agent Agreement between Dais Analytic Corporation and Legend Merchant Group, Inc., dated October 5, 2007
10.12	Consulting Agreement between Dais Analytic Corporation and Harold Mandelbaum dated August 12, 2009
14.1	Code of Ethics***

Edgar Filing: DAIS ANALYTIC CORP - Form 10-Q

- 31.1 Certification of Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002
- 31.2 Certification of Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002
- 32.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
- 32.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

- * Incorporated by reference to the exhibits included with the Registration Statement on Form S-1, File No. 333-152940, as filed August 11, 2008.
- ** Incorporated by reference to the exhibits included with the Current Report on Form 8-K, as filed March 13, 2009.
- *** Incorporated by reference to the exhibits included with Annual Report on Form 10-K, as filed March 31, 2009

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DAIS ANALYTIC CORPORATION
(Registrant)

/s/ TIMOTHY N. TANGREDI
Timothy N. Tangredi
President and Chief Executive Officer
(Principal Executive Officer)

Dated: August 14, 2009

/s/ Harold Mandelbaum
Harold Mandelbaum
Chief Financial Officer
(Principal Financial and Accounting Officer)

Dated: August 14, 2009